用于治疗良性前列腺增生症的iTind临时植入性尼丁醇装置的设备配置
Levi Godard1, Hersh Trivedi2, Gopal Narang2
1Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Expert review of medical devices
|June 6, 2025
概括
该iTind设备为良性前列腺激增症 (BPH) 提供了一种安全的,最少侵入性的治疗方法,可以保持射精功能. 虽然对BPH症状有效,但再治疗率可能高于传统手术.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗器械 医疗器械
背景情况:
- 良性前列腺增生 (BPH) 是男性普遍存在的疾病.
- 目前的BPH治疗包括改变生活方式,药物和手术.
- 最少侵入性外科治疗 (MIST) 是一个不断发展的治疗类别.
研究的目的:
- 提供对iTind设备用于BPH治疗的客观评估.
- 审查有关iTind.安全性,有效性和耐久性的已公布数据.
- 将iTind与其他BPH治疗选择进行比较.
主要方法:
- 系统地搜索主要科学数据库,以对iTind设备进行研究.
- 对已发表的文献进行分析,重点关注iTind的临床结果.
- 与已确立的BPH疗法对比iTind的比较审查.
主要成果:
- 对于某些BPH患者来说,iTind是一种安全的治疗选择,特别是那些优先考虑射精功能的人.
- 该设备在缓解BPH症状方面表现出有效性.
- 现有的数据表明,与传统的手术干预相比,iTind的再治疗率可能更高.
结论:
- 在特定的患者群体中,iTind为BPH管理提供了一种可行的最小侵入性选择.
- 需要进一步的长期数据来充分确定iTind治疗的耐用性和长期结果.
- 患者选择对于优化iTind治疗成功至关重要.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...